Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2015

English | Dutch
  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos Group
    • Letter from the management
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management
    • The Galapagos share
    • Subsequent events
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Rheumatoid arthritis
      • RA and limitations of current treatments
      • The potential of JAK inhibitors
      • Galapagos’ clinical program for filgotinib for RA
      • Previous clinical trials for filgotinib for RA
      • Jef’s story
    • Inflammatory bowel disease
      • CD and limitations of current treatments
      • The potential of JAK inhibitors for the treatment of CD
      • Clinical program for filgotinib for CD
    • Cystic fibrosis
      • The potential of CFTR modulators for the treatment of CF
      • Novel modulator combinations for treating CF
      • Nikki’s story
      • Katja’s story
    • Idiopathic pulmonary fibrosis
    • Osteoarthritis
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of Directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive Directors
      • Executive Directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other Executive Committee members
      • Shares, warrants or other rights
      • Severance payments
      • Severance payments in 2015
      • Claw-back right
    • Conflict of interests and related parties
    • Statement by the Board of Directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Fair value remeasurement of share subscription agreement
        • 9. Other financial income/expenses
        • 10. Taxes
      • Notes 11-20
        • 11. Discontinued operations
        • 12. Result per share
        • 13. Intangible assets
        • 14. Property, plant and equipment
        • 15. Research and Development incentives receivables
        • 16. Restricted cash
        • 17. Trade and other receivables and other current assets
        • 18. Cash and cash equivalents
        • 19. Share capital
        • 20. Other reserves
      • Notes 21-30
        • 21. Translation differences
        • 22. Deferred tax
        • 23. Finance lease liabilities
        • 24. Trade and other liabilities
        • 25. Provisions
        • 26. Operating lease obligations
        • 27. Off-balance sheet arrangements
        • 28. Contingent assets and liabilities
        • 29. Retirement benefit plans
        • 30. Warrant plans
      • Notes 31-36
        • 31. Related parties
        • 32. Consolidated companies as of December 31, 2015
        • 33. Company acquistions and disposals
        • 34. Financial risk management
        • 35. Auditor’s remuneration
        • 36. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor
Riding on the success of filgotinib, the JAK1 inhibitor discovered by Galapagos, we aim to advance more programs using proprietary targets toward the clinic.

Bart Filius

CFO Galapagos

You are here:

  • Home
  • Financial statements
Financial statements

Financial statements

Consolidated and nonconsolidated financial statements for 2015

previous pagenext page

Notes

Read more

Consolidated financial statements

Read more

Non-consolidated financial statements

Read more
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 25 March 2016

Galapagos Annual Report 2015 (PDF)

Download the entire report as PDF.

Download PDF (2.6 MB)
English | Dutch
  • © Copyright 2015 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
© Copyright 2015 Galapagos NV
nexxar - digital reporting evolved - Online Report